Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a type of neuroendocrine neoplasm that originate in the gastrointestinal tract and pancreas, accounting for approximately 55% to 70% of all neuroendocrine tumor cases. These tumors are most found in the foregut, midgut, and hindgut and are often linked to hormonal syndromes. The rising emphasis on early detection, targeted therapies, and personalized treatment is accelerating advancements in GEP-NETs therapeutic products. According to the gastroenteropancreatic neuroendocrine tumors (GEP-NETs) pipeline analysis by Expert Market Research, the treatment landscape is poised for notable growth in the coming years.
Major companies involved in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs) pipeline analysis include RayzeBio, Inc., Phanes Therapeutics, and others.
Leading drugs currently in the pipeline include RYZ101, 177Lu-PNT2003, and others.
The growth for gastroenteropancreatic neuroendocrine tumor (GEP-NETs) drugs is driven by the increasing clinical trials in targeted therapies, rising R&D investments, and advancements in peptide receptor radionuclide therapy (PRRT).
The Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into gastroenteropancreatic neuroendocrine tumors (GEP-NETs) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for into gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The into gastroenteropancreatic neuroendocrine tumors (GEP-NETs) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The into gastroenteropancreatic neuroendocrine tumors (GEP-NETs) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with into gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to into gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that arise from neuroendocrine cells in the gastrointestinal tract and pancreas. These tumors can occur sporadically or due to genetic syndromes and often grow slowly but may become malignant.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are treated through surgery, somatostatin analogs, targeted therapies, chemotherapy, or peptide receptor radionuclide therapy depending on tumor location, grade, and progression. In April 2024, the U.S. Food and Drug Administration approved lutetium Lu 177 dotatate for pediatric patients aged 12 years and older with somatostatin receptor-positive GEP-NETs, marking the first radiopharmaceutical approval for this population segment.
According to Baizhou Tan et al., 2024, the global incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has shown a consistent upward trend over recent decades. In the United States, incidence rates rose from 1.05 per 100,000 in 1975 to 5.45 per 100,000 by 2015. Similar patterns were observed in Canada, Switzerland, and the United Kingdom. More recent registry data from China and Japan confirm continued increases, particularly in rectal, pancreatic, and gastric NETs. Improved diagnostics and refined classifications are key factors driving these observed trends in prevalence.
This section of the report covers the analysis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II (at 35%) covers a major share of the total gastroenteropancreatic neuroendocrine tumors (GEP-NETs) clinical trials. It followed by Phase I at 29%, Phase III at 22%. This balanced pipeline distribution indicates strong research momentum across all stages, positively impacting the gastroenteropancreatic neuroendocrine tumors (GEP-NETs) market through continuous innovation and treatment advancements.
The drug molecule categories covered under the gastroenteropancreatic neuroendocrine tumors (GEP-NETs) pipeline analysis include small molecules, monoclonal antibodies, peptides, antibody-drug conjugates, and immunotherapies. The gastroenteropancreatic neuroendocrine tumors (GEP-NETs) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Radiopharmaceutical therapies are emerging as a promising drug class for treating gastroenteropancreatic neuroendocrine tumors. For instance, ITM-11, a non-carrier-added lutetium-177 edotreotide compound targeting somatostatin receptors, demonstrated a significant improvement in progression-free survival compared to everolimus in the Phase III COMPETE trial. This targeted approach offers a new treatment avenue for inoperable, progressive GEP-NETs.
The EMR report for the gastroenteropancreatic neuroendocrine tumors (GEP-NETs) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed gastroenteropancreatic neuroendocrine tumors (GEP-NETs) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) drug candidates.
RYZ101, developed by RayzeBio, Inc., is currently undergoing a global Phase 1b/3 trial (ACTION-1) to evaluate its safety, efficacy, and pharmacokinetics in patients with inoperable, well-differentiated, SSTR+ GEP-NETs progressing after prior 177Lu-SSA therapy. This alpha-emitting radiopharmaceutical, 225Ac-DOTATATE, is targeting SSTR2+ solid tumors by inducing double-strand DNA breaks, offering potential therapeutic advantage over beta-emitting agents like 177Lu-DOTATATE.
177Lu-PNT2003 is a somatostatin receptor–targeted radioligand being developed by Lantheus Holdings as a generic version of lutetium Lu 177 dotatate. The current phase aims to examine its safety and efficacy in treating SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut. It is positioned to offer a lower-cost therapeutic option, with potential 180-day U.S. marketing exclusivity upon FDA approval.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into gastroenteropancreatic neuroendocrine tumors (GEP-NETs) collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share